After adjusting for age, FLT3, IDH1, activating RAS, and NPM1 mutations, we still detected significant differences in OS of AML patients between the low and high TMEM217 expression subgroups (Fig. S2A). Here, TMEM217 is linked to acute myeloid leukemia.